Wells Fargo & Company Soleno Therapeutics Inc Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$0.14 - $0.23 $42 - $69	302 Added 86.53%	651 $0
Q1 2022 May 16, 2022	BUY	$0.22 - $0.47 $0 - $0	2 Added 0.58%	349 $0
Q3 2021 Nov 15, 2021	SELL	$0.8 - $1.12 $5 - $7	-7 Reduced 1.98%	347 $0
Q2 2021 Aug 16, 2021	SELL	$0.97 - $1.32 $17,907 - $24,368	-18,461 Reduced 98.12%	354 $0
Q1 2021 May 13, 2021	SELL	$1.24 - $3.3 $81,988 - $218,196	-66,120 Reduced 77.85%	18,815 $24,000
Q4 2020 Feb 09, 2021	SELL	$1.61 - $2.23 $32,125 - $44,497	-19,954 Reduced 19.02%	84,935 $163,000
Q3 2020 Nov 05, 2020	BUY	$1.71 - $2.51 $83,129 - $122,021	48,614 Added 86.39%	104,889 $263,000
Q2 2020 Aug 13, 2020	BUY	$1.77 - $4.23 $99,374 - $237,489	56,144 Added 42858.02%	56,275 $125,000
Q1 2020 May 14, 2020	BUY	$1.64 - $3.85 $214 - $504	131 New	131 $0

Ticker SLNO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,101,250
Market Cap $362M
Description
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing P...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.